BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20260716T150000
DTEND;TZID=Europe/London:20260716T160000
DTSTAMP:20260714T060242
CREATED:20260625T201442Z
LAST-MODIFIED:20260625T201442Z
UID:10002300-1784214000-1784217600@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Decoding complex disease through multiomics
DESCRIPTION:Complex diseases are shaped by polygenic risk\, regulatory variation\, and molecular mechanisms that cannot be fully explained by single-omics approaches. \nIn this webinar\, our expert speakers will discuss how multiomic Oxford Nanopore sequencing supports a deeper understanding of disease mechanisms\, by integrating DNA\, RNA\, and epigenetic analysis — all on a single platform. \nPLEASE NOTE: This webinar will be offered in two timezones. Please select your preferred option on the form below. \nYou will learn:\n\nHow multiomic Oxford Nanopore sequencing brings together characterisation of DNA variants\, RNA isoforms\, and DNA and RNA modifications for more comprehensive disease research.\nHow multiomic insights can support biomarker discovery and translational research into neurodegenerative conditions such as Alzheimer’s disease.\nHow Oxford Nanopore is unlocking new possibilities in RNA and cDNA sequencing\, with a new cDNA-PCR protocol generating longer\, more complete reads and more accurate isoform resolution than legacy technologies.\n\n\nMeet the speakers\nWalaa-Mohamed\, Market Segment Manager – Complex Disease\, Oxford Nanopore Technologies – Walaa is the Complex Disease Segment Market Manager at Oxford Nanopore Technologies. She works on supporting the adoption of long-read sequencing for the study of complex diseases. She has been at Oxford Nanopore Technologies for four years\, contributing to the advancement of genomics applications and translational research. Prior to joining Oxford Nanopore\, she worked as an R&D scientist at G42 on the validation phase of the Emirati Genome Project\, focusing on end-to-end workflow development and population-scale implementation. \nAshan Musafer\, Senior Field Application Scientist\, Oxford Nanopore Technologies – Ashan Musafer is a Senior Field Application Scientist at Oxford Nanopore Technologies with over a decade of expertise in translational genomics and epigenetics. He holds a Bachelor’s degree in Biomedical science from Monash University and a Master’s degree in Laboratory Medicine from the Royal Melbourne Institute of Technology (RMIT). Over the past 3 years at Oxford Nanopore\, Ashan has focused on technical enablement while supporting the planning\, implementation and execution of various genomic initiatives across the Gulf and Central Asian region. \nPatrick-Murphy\, Market Segment Manager – Single Cell\, Oxford Nanopore Technologies – At Oxford Nanopore Technologies\, Patrick Murphy works on single cell and bulk transcriptomics applications of Oxford Nanopore sequencing. He focuses on helping researchers understand where Oxford Nanopore sequencing approaches can add value to their transcriptomics studies\, including analysis of full-length RNA molecules\, isoforms\, splice variation\, and fusion transcripts. \n\nClick Here
URL:https://www.dementiaresearcher.nihr.ac.uk/event/decoding-complex-disease-through-multiomics/
LOCATION:Online\, United Kingdom
CATEGORIES:Workshop
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2023/01/Nanopore-Technology.png
END:VEVENT
END:VCALENDAR